|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preoperative growth hormone levels (P = 0.017), growth hormone nadir (P = 0.003), and tumor size (P = 0.026) were the most likely influencing factors associated with the surgical remission rate.
|
29360584 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Gsp mutation is one of the major intrinsic defects in the pathogenesis of growth hormone-secreting pituitary tumors and the identification of gsp mutation can be a reference for classification and prognosis of GH tumors.
|
11189233 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The use of growth hormone (GH) in patients with GH deficiency induced by pituitary adenoma is widely accepted, but the safety of this mitogenic hormone, particularly in patients with residual tumor after neurosurgery, continues to be a concern.
|
15891957 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of the long non-coding RNA H19 and MALAT-1 in growth hormone-secreting pituitary adenomas and its relationship to tumor behavior.
|
29604339 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that there is, in general, little difference in the clinical and biochemical characteristics between gsp-positive and gsp-negative human pituitary GH-secreting tumors.
|
8396223 |
1993 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Because a T-to-A polymorphism in the human GH1 gene at position 1663 is putatively associated with lower levels of GH and IGF-I, we investigated the relationship of this polymorphism to the risk of colorectal neoplasia.
|
11904318 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma.
|
21849525 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, we have demonstrated that SUR mRNA expression is common in several types of silent pituitary adenomas and in functional tumors that secrete GH.
|
9666339 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor size and GH-7 were significantly associated with biological remission and tumor relapse after GTR, respectively.
|
31368083 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Her GH level dropped to normal with a >90% decrease in tumor size, after 1-year treatment.
|
30639490 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We studied the effect of GH on longevity and tumour formation in Atm-deficient mice, an established model of the human cancer prone syndrome ataxia telangiectasia (AT).
|
19626507 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In acromegaly, tumors secreting growth hormone had only an aneuploid DNA pattern in 41 per cent of the cases, whereas 67 per cent of the tumors with concomitant secretion of growth hormone and prolactin were aneuploid.
|
3993857 |
1985 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The available data suggest that GH expression by tumour cells is associated with the aetiology and progression of various cancers such as endometrial, breast, liver, prostate, and colon cancer.
|
28622965 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study we quantified SSTR2 and SSTR5 mRNA expression and the GH-suppressive effects of somatostatin-14; octreotide; a SSTR2-preferential compound, BIM-23197; a SSTR5-preferential compound, BIM-23268; and a new SSTR2- and SSTR5-bispecific compound, BIM-23244, in GH-secreting tumors classified as either full responders to octreotide (n = 5) or partially sensitive to octreotide (n = 5).
|
11231991 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pathology and follow-up outcomes were applied as the gold standard for differentiating between 76 patients with pituitary microadenomas (38 prolactin-producing tumors, 17 adrenocorticotropic hormone adenomas and 21 growth hormone-producing tumors) and 20 patients with normal pituitary glands.
|
30944618 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subgroup analysis was performed for patients who had biochemical or radiological "discordance"-patients who achieved biochemical remission but with incongruent insulin-like growth factor 1 (IGF-1)/GH or residual tumor on MRI.
|
31604330 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All the children with GH excess had a tumor involving the chiasma.
|
28631895 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The great majority of growth hormone (GH)-secreting pituitary tumors are sporadic, though a few occur with a familial aggregation, either as a component of multiple endocrine neoplasia, type 1 (MEN1) or Carney Complex, or when unassociated with other tumors, as isolated familial somatotropinomas (IFS).
|
15761658 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunochemistry of the tumour was positive for hypothalamic growth hormone releasing hormone (GHRH) and pituitary hormones, such as GH and ACTH.
|
28232376 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Indeed, a significantly higher expression of SSTR2 in DG compared to in SG tumors likely explains the better response of DG tumors to the normalization of growth hormone and insulin-like growth factor-1 under SA.
|
30531694 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The pre-operative mean GH level was 71.23 ± 3.29 μg/L, which was positively correlated with tumor volume (r = 0.751, P < 0.01).
|
29238923 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Following surgery, pathology revealed a collision tumor; the dominant lesion was positive for GH, βTSH, βFSH, and αSU and expressed both Pit-1 and SF-1.The smaller lesion was a corticotroph tumor.
|
30610567 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Growth hormone (GH)-producing pituitary adenomas (PAs) in childhood or young adulthood are rare, and the details surrounding these tumors remain enigmatic.
|
28849339 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The third acromegalic brother had a normal GH value and evidence of panhypopituitarism; he had a small intrasellar tumor and a partially empty sella.
|
3950729 |
1986 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The high expression of somatostatin receptor 2 (SST2) in growth hormone (GH)-secreting tumors represents the rationale for the clinical use of somatostatin analogs (SSAs) in acromegaly.
|
31574507 |
2019 |